Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
22
06
2020
accepted:
22
10
2020
revised:
14
10
2020
pubmed:
7
11
2020
medline:
12
10
2021
entrez:
6
11
2020
Statut:
ppublish
Résumé
Patients at clinical high-risk (CHR) for psychosis show elevations in [
Identifiants
pubmed: 33154566
doi: 10.1038/s41380-020-00934-w
pii: 10.1038/s41380-020-00934-w
doi:
Substances chimiques
Receptors, Dopamine D3
0
Methylphenidate
207ZZ9QZ49
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2504-2513Informations de copyright
© 2020. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70:107–20.
pubmed: 23165428
pmcid: 4356506
doi: 10.1001/jamapsychiatry.2013.269
Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, et al. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry. 2011;168:800–5.
pubmed: 21498462
pmcid: 3150607
doi: 10.1176/appi.ajp.2011.10081191
Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR, et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry. 2011;168:1311–7.
pubmed: 21768612
pmcid: 3682447
doi: 10.1176/appi.ajp.2011.11010160
Egerton A, Chaddock CA, Winton-Brown TT, Bloomfield MA, Bhattacharyya S, Allen P, et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry. 2013;74:106–12.
pubmed: 23312565
doi: 10.1016/j.biopsych.2012.11.017
Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66:13–20.
pubmed: 19124684
doi: 10.1001/archgenpsychiatry.2008.514
Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A. Pathway-specific dopamine abnormalities in schizophrenia. Biol Psychiatry. 2017;81:31–42.
pubmed: 27206569
doi: 10.1016/j.biopsych.2016.03.2104
Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry. 2011;16:885–6.
pubmed: 21358709
doi: 10.1038/mp.2011.20
Bloemen OJ, de Koning MB, Gleich T, Meijer J, de Haan L, Linszen DH, et al. Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at ultra high risk for psychosis. Eur Neuropsychopharmacol. 2013;23:126–32.
pubmed: 22591910
doi: 10.1016/j.euroneuro.2012.04.015
Allen P, Luigjes J, Howes OD, Egerton A, Hirao K, Valli I, et al. Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. Schizophr Bull. 2012;38:1268–76.
pubmed: 22290265
pmcid: 3494046
doi: 10.1093/schbul/sbr194
Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121.
pubmed: 11160455
pmcid: 6763805
doi: 10.1523/JNEUROSCI.21-02-j0001.2001
Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S, et al. Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab. 2007;27:857–71.
pubmed: 17033687
doi: 10.1038/sj.jcbfm.9600411
Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, et al. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9 -ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem. 2005;48:4153–60.
pubmed: 15943487
doi: 10.1021/jm050155n
Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, et al. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry. 2010;68:392–9.
pubmed: 20599188
doi: 10.1016/j.biopsych.2010.04.038
Girgis RR, Xu X, Miyake N, Easwaramoorthy B, Gunn RN, Rabiner EA, et al. In vivo binding of antipsychotics to D(3) and D(2) receptors: a PET study in baboons with [(11)C]-(+)-PHNO. Neuropsychopharmacology. 2011;36:887–95.
pubmed: 21178982
doi: 10.1038/npp.2010.228
Boileau I, Payer D, Chugani B, Lobo DS, Houle S, Wilson AA, et al. In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [(11)C]-(+)-PHNO. Mol Psychiatry. 2013;19:1305–13.
pubmed: 24322203
doi: 10.1038/mp.2013.163
Gallezot JD, Kloczynski T, Weinzimmer D, Labaree D, Zheng MQ, Lim K, et al. Imaging nicotine- and amphetamine-induced dopamine release in rhesus monkeys with [(11)C]PHNO vs [(11)C]raclopride PET. Neuropsychopharmacology. 2014;39:866–74.
pubmed: 24220025
doi: 10.1038/npp.2013.286
Halldin C, Farde L, Hogberg T, Mohell N, Hall H, Suhara T, et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med. 1995;36:1275–81.
pubmed: 7790956
Narendran R, Frankle WG, Mason NS, Rabiner EA, Gunn RN, Searle GE, et al. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride. Synapse. 2009;63:447–61.
pubmed: 19217025
doi: 10.1002/syn.20628
Chou YH, Halldin C, Farde L. Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: a PET study. Synapse. 2000;38:138–43.
pubmed: 11018787
doi: 10.1002/1098-2396(200011)38:2<138::AID-SYN4>3.0.CO;2-7
Olsson H, Halldin C, Swahn CG, Farde L. Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab. 1999;19:1164–73.
pubmed: 10532641
doi: 10.1097/00004647-199910000-00013
Narendran R, Mason NS, May MA, Chen CM, Kendro S, Ridler K, et al. Positron emission tomography imaging of dopamine D2/3 receptors in the human cortex with [(1)(1)C]FLB 457: reproducibility studies. Synapse. 2011;65:35–40.
pubmed: 20506186
pmcid: 2939958
doi: 10.1002/syn.20813
Sudo Y, Suhara T, Inoue M, Ito H, Suzuki K, Saijo T, et al. Reproducibility of [11 C]FLB 457 binding in extrastriatal regions. Nucl Med Commun. 2001;22:1215–21.
pubmed: 11606887
doi: 10.1097/00006231-200111000-00008
Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I, et al. Increased stress-induced dopamine release in psychosis. Biol Psychiatry. 2012;71:561–7.
pubmed: 22133268
doi: 10.1016/j.biopsych.2011.10.009
Mizrahi R, Kenk M, Suridjan I, Boileau I, George TP, McKenzie K, et al. Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology. 2014;39:1479–89.
pubmed: 24385130
pmcid: 3988552
doi: 10.1038/npp.2013.347
Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29:703–15.
pubmed: 14989408
doi: 10.1093/oxfordjournals.schbul.a007040
McGlashan TH, Miller TJ, Woods SW, Hoffman RE, Davidson LA. Scale for the assessment of prodromal symptoms and states. In: Miller T, Mednick, SA, McGlashan, TH, Liberger, J, Johannessen, JO, editor Early intervention in psychotic disorders. Dordrecht: Kluwer Academic Publishers; 2001. p. 135–49.
Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, et al. Prospective diagnosis of the prodrome for schizophrenia: preliminary evidence of interrater reliability and predictive validity using operational criteria and a structured interview. Am J Psychiatry. 2002;159:863–65.
pubmed: 11986145
doi: 10.1176/appi.ajp.159.5.863
Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, et al. Prodromal assessment with the Sstructured Interview for Prodromal Syndromes: Predictive validity, interrater reliability, and training to reliability. Schizophrenia Bull. 2003;29:703–15.
doi: 10.1093/oxfordjournals.schbul.a007040
Rosen JL, Woods SW, Miller TJ, McGlashan TH. Prospective observations of emerging psychosis. J Nerv Ment Dis. 2002;190:133–41.
pubmed: 11923647
doi: 10.1097/00005053-200203000-00001
McGlashan TH, Walsh BC, Woods SW. Structured Interview for Psychosis Risk Syndromes. New Haven, CT: PRIME Research Clinic, Yale School of Medicine; 2014.
Nurnberger JI Jr, Blejar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. Arch Gen Psychiatry. 1994;51:849–59.
pubmed: 7944874
doi: 10.1001/archpsyc.1994.03950110009002
First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics Research NYSPI; 2002.
Guy W. Clinical global impressions. In: Guy W, editor. ECDEU assessment manual for psychopharmacology: revised, ADM 76-338. Washington, DC: Department of Health, Education, and Welfare; 1976. p. 217–22.
Martinez D, Carpenter KM, Liu F, Slifstein M, Broft A, Friedman AC, et al. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am J Psychiatry. 2011;168:634–41.
pubmed: 21406463
pmcid: 3235735
doi: 10.1176/appi.ajp.2010.10050748
SPM Online Bibliography. http://www.fil.ion.ucl.ac.uk/spm/doc/biblio/ . Accessed 2020.
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.
pubmed: 17519979
doi: 10.1038/sj.jcbfm.9600493
Pinheiro J, Bates D, DebRoy S, Sarkar D, Team RC. nlme: linear and nonlinear fixed effects models. 2020. https://CRAN.R-project.org/package=nlme .
Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006;59:1151–9.
pubmed: 16566899
doi: 10.1016/j.biopsych.2005.09.018
Suridjan I, Rusjan P, Addington J, Wilson AA, Houle S, Mizrahi R. Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task. J Psychiatry Neurosci. 2013;38:98–106.
pubmed: 23010256
pmcid: 3581597
doi: 10.1503/jpn.110181
McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019;42:205–20.
pubmed: 30621912
pmcid: 6401206
doi: 10.1016/j.tins.2018.12.004
Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab. 2003;23:285–300.
pubmed: 12621304
doi: 10.1097/01.WCB.0000048520.34839.1A
Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 1987;91:415–33.
pubmed: 2884687
doi: 10.1007/BF00216006
Simpson EH, Kellendonk C. Insights about striatal circuit function and schizophrenia from a mouse model of dopamine D2 receptor upregulation. Biol Psychiatry. 2017;81:21–30.
pubmed: 27720388
doi: 10.1016/j.biopsych.2016.07.004
Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148:1474–86.
pubmed: 1681750
doi: 10.1176/ajp.148.11.1474
Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 2013;78:81–93.
pubmed: 23583108
pmcid: 3966570
doi: 10.1016/j.neuron.2013.02.011
Schobel SA, Lewandowski NM, Corcoran CM, Moore H, Brown T, Malaspina D, et al. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry. 2009;66:938–46.
pubmed: 19736350
pmcid: 2797730
doi: 10.1001/archgenpsychiatry.2009.115
Ho NF, Holt DJ, Cheung M, Iglesias JE, Goh A, Wang M, et al. Progressive decline in hippocampal CA1 volume in individuals at ultra-high-risk for psychosis who do not remit: findings from the longitudinal youth at risk study. Neuropsychopharmacology. 2017;42:1361–70.
pubmed: 28079061
pmcid: 5437892
doi: 10.1038/npp.2017.5
Bossong MG, Antoniades M, Azis M, Samson C, Quinn B, Bonoldi I, et al. Association of hippocampal glutamate levels with adverse outcomes in individuals at clinical high risk for psychosis. JAMA Psychiatry. 2019;76:199–207.
pubmed: 30427993
doi: 10.1001/jamapsychiatry.2018.3252
Kraguljac NV, White DM, Reid MA, Lahti AC. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry. 2013;70:1294–302.
pubmed: 24108440
pmcid: 7891898
doi: 10.1001/jamapsychiatry.2013.2437
Provenzano FA, Guo J, Wall MM, Feng X, Sigmon HC, Brucato G, et al. Hippocampal pathology in clinical high-risk patients and the onset of schizophrenia. Biol Psychiatry. 2020;87:234–42.
pubmed: 31771861
doi: 10.1016/j.biopsych.2019.09.022
Small SA, Schobel SA, Buxton RB, Witter MP, Barnes CA. A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci. 2011;12:585–601.
pubmed: 21897434
pmcid: 3312472
doi: 10.1038/nrn3085
Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010;67:231–9.
pubmed: 20194823
doi: 10.1001/archgenpsychiatry.2010.10
Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35:217–38.
pubmed: 19710631
doi: 10.1038/npp.2009.110
Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser J, Kegeles LS, Pratap M, et al. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry. 2001;50:313–22.
pubmed: 11543733
doi: 10.1016/S0006-3223(01)01089-7
Busto UE, Redden L, Mayberg H, Kapur S, Houle S, Zawertailo LA. Dopaminergic activity in depressed smokers: a positron emission tomography study. Synapse. 2009;63:681–9.
pubmed: 19360907
pmcid: 2761223
doi: 10.1002/syn.20646
Schneier FR, Slifstein M, Whitton AE, Pizzagalli DA, Reinen J, McGrath PJ, et al. Dopamine release in antidepressant-naive major depressive disorder: a multimodal [(11)C]-(+)-PHNO positron emission tomography and functional magnetic resonance imaging study. Biol Psychiatry. 2018;84:563–73.
pubmed: 30041971
pmcid: 6347467
doi: 10.1016/j.biopsych.2018.05.014
Slifstein M, Narendran R, Hwang DR, Sudo Y, Talbot PS, Huang YY. et al. Effect of amphetamine on [F-18]fallypride in vivo binding to D-2 receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies. Synapse. 2004;54:46–63.
pubmed: 15300884
doi: 10.1002/syn.20062
Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T, et al. Affinity and selectivity of [(1)(1)C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse. 2012;66:489–500.
pubmed: 22213512
doi: 10.1002/syn.21535
Slifstein M, Abi-Dargham A, Girgis RR, Suckow RF, Cooper TB, Divgi CR, et al. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [(11)C]-(+)-PHNO. Psychopharmacology. 2020;237:519–27.
pubmed: 31773210
doi: 10.1007/s00213-019-05387-w
Berry AS, Shah VD, Furman DJ, White RL 3rd, Baker SL, O’Neil JP, et al. Dopamine synthesis capacity is associated with D2/3 receptor binding but not dopamine release. Neuropsychopharmacology. 2018;43:1201–11.
pubmed: 28816243
doi: 10.1038/npp.2017.180
Nour MM, McCutcheon R, Howes OD. The relationship between dopamine synthesis capacity and release: implications for psychosis. Neuropsychopharmacology. 2018;43:1195–96.
pubmed: 29670249
pmcid: 5916363
doi: 10.1038/npp.2017.293
Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, Siessmeier T, Heinz A, et al. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J Neurosci. 2007;27:8080–7.
pubmed: 17652599
pmcid: 6672729
doi: 10.1523/JNEUROSCI.0805-07.2007
Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry. 2015;72:316–24.
pubmed: 25651194
pmcid: 4768742
doi: 10.1001/jamapsychiatry.2014.2414
Schifani C, Tseng HH, Kenk M, Tagore A, Kiang M, Wilson AA, et al. Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosis. Brain. 2018;141:2213–24.
pubmed: 29860329
pmcid: 6022671
doi: 10.1093/brain/awy133
Tseng HH, Watts JJ, Kiang M, Suridjan I, Wilson AA, Houle S, et al. Nigral stress-induced dopamine release in clinical high risk and antipsychotic-naive schizophrenia. Schizophr Bull. 2018;44:542–51.
pubmed: 29036383
doi: 10.1093/schbul/sbx042
Cassidy CM, Zucca FA, Girgis RR, Baker SC, Weinstein JJ, Sharp ME, et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc Natl Acad Sci USA. 2019;116:5108–17.
pubmed: 30796187
pmcid: 6421437
doi: 10.1073/pnas.1807983116
Brucato G, Masucci MD, Arndt LY, Ben-David S, Colibazzi T, Corcoran CM, et al. Baseline demographics, clinical features and predictors of conversion among 200 individuals in a longitudinal prospective psychosis-risk cohort. Psychol Med. 2017;47:1923–35.
pubmed: 28249639
pmcid: 5893280
doi: 10.1017/S0033291717000319
Small SA. Isolating pathogenic mechanisms embedded within the hippocampal circuit through regional vulnerability. Neuron. 2014;84:32–9.
pubmed: 25277453
pmcid: 4185396
doi: 10.1016/j.neuron.2014.08.030
Lieberman JA, Small SA, Girgis RR. Early detection and preventive intervention in schizophrenia: from fantasy to reality. Am J Psychiat. 2019;176:794–810.
pubmed: 31569988
doi: 10.1176/appi.ajp.2019.19080865